NCT05436912View on ClinicalTrials.gov

A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

December 10, 2018

Primary Completion Date

October 4, 2019

Study Completion Date

October 30, 2019

Conditions
HealthyHepatic Impairment
Interventions
DRUG

Selpercatinib

Administered orally.

Trial Locations (7)

32132

Riverside Clinical Research, Edgewater

32809

Orlando Clinical Research Center, Orlando

33014

Clinical Pharmacology of Miami, Miami

78215

The Texas Liver Institute, San Antonio

91754

National Institute of Clinical Research, Monterey Park

92780

Orange County Research Center, Tustin

92801

Orange County Research Institute, Anaheim

Sponsors

Collaborators (1)

Loxo Oncology, Inc.
All Listed Sponsors
collaborator

Loxo Oncology, Inc.

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY

NCT05436912 - A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants | Biotech Hunter | Biotech Hunter